WallStSmart

Ardent Health Partners, Inc. (ARDT)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 795% more annual revenue ($56.58B vs $6.32B). NVS leads profitability with a 23.9% profit margin vs 2.1%. ARDT trades at a lower P/E of 10.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).

ARDT

Hold

43

out of 100

Grade: D

Growth: 3.3Profit: 5.5Value: 6.7Quality: 7.0
Piotroski: 6/9Altman Z: 2.08

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARDT.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARDT2 strengths · Avg: 10.0/10
P/E RatioValuation
10.0x10/10

Attractively priced relative to earnings

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

ARDT4 concerns · Avg: 2.8/10
Market CapQuality
$1.38B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.1%3/10

2.1% margin — thin

Debt/EquityHealth
1.843/10

Elevated debt levels

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ARDT

The strongest argument for ARDT centers on P/E Ratio, Price/Book.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : ARDT

The primary concerns for ARDT are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.84 is elevated, increasing financial risk. Thin 2.1% margins leave little buffer for downturns.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

ARDT profiles as a value stock while NVS is a declining play — different risk/reward profiles.

ARDT is growing revenue faster at -0.1% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 43/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ardent Health Partners, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a premier healthcare organization focused on delivering high-quality, patient-centered care through a comprehensive network of hospitals and outpatient facilities. Renowned for its extensive portfolio of acute care hospitals, Ardent is dedicated to innovating healthcare solutions that meet the diverse and evolving needs of communities. With a solid financial structure and a strategic vision for growth, the company is well-positioned to enhance access to healthcare and improve patient outcomes in a complex and dynamic industry landscape.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?